Lotilaner is under clinical development by Tarsus Pharmaceuticals and currently in Phase II for Meibomian Blepharitis. According to GlobalData, Phase II drugs for Meibomian Blepharitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Lotilaner LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lotilaner overview

Lotilaner (Xdemvy) belongs to a member of isoxazoline class of drugs. It is formulated as solution drops for ophthalmic route of administration. Xdemvy is indicated for the treatment of Demodex blepharitis.

Lotilaner is under development for the treatment of demodex blepharitis and meibomian gland dysfunction. It is administered through topical, ophthalmic routes as solution and drops. It is a reformulation veterinary drug. It targets parasite-specific GABA-Cl channels.

Tarsus Pharmaceuticals overview

Tarsus Pharmaceuticals is a biopharmaceutical company that is involved in development and commercialization of therapeutics related to eye care. It is developing novel therapeutics for treatment of blepharitis which is caused by the infestation of Demodex mites. The company having the product pipeline for Meibomian Gland Disease, Rosacea, Lyme Disease and Malaria. The company is headquartered in Irvine, California, the US.

For a complete picture of Lotilaner’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.